Uramustine-Uracil-mustard-DataSheet-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEUramustineCat. No.: HY-13544CAS No.: 66-75-1Synonyms: Uracil mustard分式: CHClNO分量: 252.1作靶点: DNA Alkylator/Crosslinker作通路: Cell Cycle/DNA Damage储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO

2、: 29 mg/mL (115.03 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 3.9667 mL 19.8334 mL 39.6668 mL5 mM 0.7933 mL 3.9667 mL 7.9334 mL10 mM 0.3967 mL 1.9833 mL 3.9667 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Uramustine种可服的烷化剂 (a

3、lkylator)，可于治疗淋巴瘤、慢性淋巴性病和板增多症。IC50 & Target DNA Alkylator 1体外研究Uramustine is an oral alkylating agent, with potent antitumor activity. Uramustine inhibits human chronic1/2 Master of Small Molecules 您边的抑制剂师www.MedChemEmyeloid leukaemia K562 cell line, with an IC50 of 5.1 M.PROTOCOLCell Assay 1 The K5

4、62 human chronic myeloid leukemia cells are maintained in RPM1 1640 medium supplemented with10% fetal calf serum and 2 mM glutamine at 37C in a humidified atmosphere containing 5% CO2 and areincubated with a specified dose of drug for 1 h at 37C in the dark. The incubation is terminated bycentrifuga

5、tion (5 min, 300 g), and the cells are washed once with drug-free medium. Following theappropriate Uramustine treatment, the cells are transferred to 96-well microtiter plates, with 104 cells per welland 8 wells per sample. Plates are then kept in the dark at 3C in a humidified atmosphere containing

6、 5%CO2. The assay is based on the ability of viable cells to reduce a yellow soluble tetrazolium salt, MTT to aninsoluble purple formazan precipitate. Following incubation of the plates for 4 days (to allow control cells toincrease in number by 10-fold), 20 L of a 5 mg/mL solution of MTT in phosphat

7、e-buffered saline is added toeach well and the plates are further incubated for 5 h. The plates are then centrifuged for 5 min at 300 g, andthe bulk of the medium is pipetted from the cell pellet, leaving 1020 L per well. A total of 200 L of DMSOis added to each well, and the samples are agitated to

8、 ensure complete mixing. The optical density is thenread at a wavelength of 550 nm on a plate reader, and the doseresponse curve is constructed. For eachcurve, an IC50 value is read as the dose required to reduce the final optical density to 50% of the controlvalue 1.MCE has not independently confir

9、med the accuracy of these methods. They are for reference only.户使本产品发表的科研献 J Mol Med (Berl). 2019 Jun 14.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Baraldi PG, et al. Design, synthesis, and biological activity of hybrid compounds between uramustine and DNA minor groove binderdistamycin A. J Med Chem. 2002 Aug 15;45(17):3630-3638.McePdfHeightCaution: Product has not been fully validated for me